CRMD vs. VRCA, INZY, AKBA, ERAS, TERN, CTNM, XOMA, RAPT, AQST, and KMDA
Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Verrica Pharmaceuticals (VRCA), Inozyme Pharma (INZY), Akebia Therapeutics (AKBA), Erasca (ERAS), Terns Pharmaceuticals (TERN), Contineum Therapeutics (CTNM), XOMA (XOMA), RAPT Therapeutics (RAPT), Aquestive Therapeutics (AQST), and Kamada (KMDA). These companies are all part of the "pharmaceutical preparations" industry.
CorMedix (NASDAQ:CRMD) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations.
Verrica Pharmaceuticals received 147 more outperform votes than CorMedix when rated by MarketBeat users. However, 70.00% of users gave CorMedix an outperform vote while only 64.66% of users gave Verrica Pharmaceuticals an outperform vote.
CorMedix has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -1,307.47%. CorMedix's return on equity of -72.31% beat Verrica Pharmaceuticals' return on equity.
CorMedix currently has a consensus target price of $13.00, indicating a potential upside of 141.64%. Verrica Pharmaceuticals has a consensus target price of $11.25, indicating a potential upside of 68.41%. Given CorMedix's higher probable upside, analysts plainly believe CorMedix is more favorable than Verrica Pharmaceuticals.
In the previous week, CorMedix had 5 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 6 mentions for CorMedix and 1 mentions for Verrica Pharmaceuticals. CorMedix's average media sentiment score of 0.28 beat Verrica Pharmaceuticals' score of 0.00 indicating that CorMedix is being referred to more favorably in the media.
34.2% of CorMedix shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 4.6% of CorMedix shares are held by insiders. Comparatively, 41.5% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
CorMedix has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500.
CorMedix has higher earnings, but lower revenue than Verrica Pharmaceuticals. CorMedix is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
CorMedix beats Verrica Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get CorMedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CorMedix Competitors List
Related Companies and Tools
